Carolina Garrido Pavon

List of Publications by Year
in descending order

49	2,148	186265	233421
papers	citations	28 h-index	45 g-index

53	53	53	2953
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nature Reviews Microbiology, 2014, 12, 750-764.	28.6	247
2	Dual-Affinity Re-Targeting proteins direct T cellâ€“mediated cytolysis of latently HIV-infected cells. Journal of Clinical Investigation, 2015, 125, 4077-4090.	8.2	124
3	Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. Journal of Clinical Microbiology, 2008, 46, 887-891.	3.9	98
4	Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. Journal of Virology, 2018, 92, .	3.4	96
5	Dried Blood Spots Perform Well in Viral Load Monitoring of Patients Who Receive Antiretroviral Treatment in Rural Tanzania. Clinical Infectious Diseases, 2009, 49, 976-981.	5.8	87
6	Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. Journal of Infectious Diseases, 2015, 212, 258-263.	4.0	86
7	High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. Aids, 2007, 21, 2503-2511.	2.2	66
8	Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. Journal of Clinical Microbiology, 2009, 47, 1031-1036.	3.9	66
9	Peripheral VÎ³9VÎ´2 T Cells Are a Novel Reservoir of Latent HIV Infection. PLoS Pathogens, 2015, 11, e1005201.	4.7	66
10	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. Journal of Antimicrobial Chemotherapy, 2010, 65, 1486-1492.	3.0	63
11	Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. Antimicrobial Agents and Chemotherapy, 2012, 56, 2873-2878.	3.2	62
12	Gold nanoparticles to improve HIV drug delivery. Future Medicinal Chemistry, 2015, 7, 1097-1107.	2.3	60
13	Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication. Nature Immunology, 2021, 22, 423-433.	14.5	59
14	HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4ÂC. Journal of Antimicrobial Chemotherapy, 2008, 61, 1217-1220.	3.0	57
15	Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. Journal of Antimicrobial Chemotherapy, 2010, 65, 320-326.	3.0	54
16	Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. Journal of Antimicrobial Chemotherapy, 2008, 61, 694-698.	3.0	53
17	Improvement in the determination of HIVâ€1 tropism using the V3 gene sequence and a combination of bioinformatic tools. Journal of Medical Virology, 2009, 81, 763-767.	5.0	50
18	Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients â€“ Impact of HIV subtypes and prior raltegravir experience. Antiviral Research, 2011, 90, 164-167.	4.1	48

#	Article	IF	Citations
19	HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Frontiers in Immunology, 2016, 7, 356.	4.8	47
20	Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. Molecular Therapy, 2015, 23, 387-395.	8.2	46
21	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. JCI Insight, 2021, 6, .	5.0	45
22	Raltegravir and Etravirine Are Active against HIV Type 1 Group O. AIDS Research and Human Retroviruses, 2009, 25, 225-227.	1.1	41
23	Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay. Journal of Clinical Microbiology, 2012, 50, 569-572.	3.9	41
24	Antiviral effect of raltegravir on HTLV-1 carriers. Journal of Antimicrobial Chemotherapy, 2012, 67, 218-221.	3.0	39
25	Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 241-244.	2.1	38
26	Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. AIDS Research and Human Retroviruses, 2007, 23, 879-885.	1.1	35
27	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science Immunology, 2021, 6, .	11.9	34
28	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. Scientific Reports, 2020, 10, 5134.	3.3	32
29	Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy, 2007, 60, 1409-1410.	3.0	31
30	Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. Journal of Clinical Virology, 2009, 46, 173-175.	3.1	30
31	Î³Î´ T cells: an immunotherapeutic approach for HIV cure strategies. JCI Insight, 2018, 3, .	5.0	27
32	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. Journal of Clinical Investigation, 2020, 130, 5157-5170.	8.2	22
33	Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation. PLoS Pathogens, 2020, 16, e1008954.	4.7	22
34	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. Aids, 2019, 33, 605-613.	2.2	21
35	Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. Clinical Infectious Diseases, 2008, 46, 1782-1785.	5.8	19
36	Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. AIDS Research and Human Retroviruses, 2012, 28, 156-164.	1.1	18

#	Article	IF	Citations
37	Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. AIDS Research and Human Retroviruses, 2009, 25, 967-972.	1.1	14
38	HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System. Journal of Antimicrobial Chemotherapy, 2011, 66, 260-264.	3.0	14
39	New therapeutic strategies for raltegravir. Journal of Antimicrobial Chemotherapy, 2010, 65, 218-223.	3.0	11
40	Role of atazanavir in the treatment of HIV infection. Therapeutics and Clinical Risk Management, 2009, 5, 99-116.	2.0	11
41	Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. Journal of Clinical Virology, 2011, 50, 148-152.	3.1	9
42	Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. Aids, 2012, 26, 551-557.	2.2	9
43	Translational challenges in targeting latent HIV infection and the CNS reservoir problem. Journal of NeuroVirology, 2015, 21, 222-226.	2.1	9
44	Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers. Virus Research, 2017, 228, 141-146.	2.2	9
45	Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. Aids, 2008, 22, 311-313.	2.2	8
46	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68.	2.0	7
47	Different disease progression rate according to HIV-1 subtype. Future HIV Therapy, 2008, 2, 319-322.	0.4	2
48	Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure. Frontiers in Immunology, 0, 13, .	4.8	2
49	Editorial: Immunotherapies Towards HIV Cure. Frontiers in Cellular and Infection Microbiology, 2021, 11, 655363.	3.9	0